Please login to the form below

Not currently logged in
Email:
Password:

Michael Fleming joins biosimilars firm Coherus

He has experience at Elan, Genentech and GSK

Coherus Biosciences has named Michael Fleming as senior VP, commercial strategy.

Fleming was most recently at Elan where he was head of commercial and of the company's Tysabri (natalizumab) franchise.

He joins Coherus as it begins to advance its pipeline of biosimilars towards commercialisation, a process that has already seen it sign an alliance with Baxter to develop a biosimilar version of Amgen and Pfizer's big-selling arthritis and psoriasis drug Enbrel (etanercept).

“Michael's experience in building commercial operations and his knowledge of markets and health systems are of immediate importance,” said Danny Lanfear, CEO of Coherus.

“He will play a key role in defining strategies that effectively maximise the commercial potential of our products.”

Fleming gained experience in commercialising biological medicines during his time leading the strategy for Elan's multiple sclerosis drug Tysabri.

His other experience includes senior commercial roles at GlaxoSmithKline, Genentech, Nuvelo, Agendia and Campbell Alliance.

1st May 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics